ArticleJournal of the American Association for Laboratory Animal Science : JAALAS2026
Assessing Ethiqa XR Sterility Past the "Beyond-Discard Date" Under Conditions of Maximum Usage.
Article in Journal of the American Association for Laboratory Animal Science : JAALAS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ethiqa XR is an FDA-indexed, extended-release, lipid-bound buprenorphine formulation providing 72 hours of opioid analgesia with a 90-day postbroach discard date. For small rodent studies, the standard vial frequently provides more drug than can be used within the 90-day labeled discard date, which can limit cost-effectiveness for researchers. This study evaluated whether sterility could be preserved for an additional 90 days beyond the labeled discard date through monthly testing for bacterial and fungal contamination, in addition to the presence of endotoxins. Twice weekly, each vial was wiped with 70% isopropyl alcohol, and a 20-gauge needle was inserted and then withdrawn, with samples removed from the vials at time points up to 180 days. All vials consistently remained free of bacterial, fungal, and endotoxin contamination throughout the study period and were sterile up to the final assessment at 180 days postbroaching. The concentration or efficacy of Ethiqa XR were not evaluated during this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.